NGS and Sequence Analysis with Biopython for Prospective Brain Cancer Therapeutic Studies

Abstract

Abstract: Malignant primary brain tumour in adults and in analysis driven by variousgenomic alterations. Next generation sequencing (NGS) provides about the geneticlandscape of tumours and might detect targetable mutations. Genomic DNA wasextracted from blood samples or tumor tissues number of biological pathways incancer involve the products of genes that are not mutated, but epigenetically whenwe found regulated, for example by altered transcription factor availability,repressor activity or gene methylation receptor-type protein tyrosine phosphatases(RPTPs) comprises PTPRZ and PTPRG,primary human glioblastomas suggested aclose association between PTPRZ1 (human PTPRZ) expression and cancerstemness. The functional roles of PTPRZ activity in glioma that sphere-forming cellsin human U251 glioblastoma cell lines showed high expression levels of PTPRZ-B.Potential PTPRZ1-MET fusion, that is caused when PTPRZ1 and the MET oncogene are fused in 8% to 16% of gliomas and is linked to a less favorable outcome nevertheless is also a promising biomarker for kinase inhibitor therapy. In accordance to the studies that are currently available, receptor-type tyrosine-protein phosphatase zeta (PTPRZ1) is found in various tumour tissues and plays a role in migration, cell proliferation, the EMT and adhesions, as well as treatment resistance by binding with a variety of substances.